Opthea Limited (OPT)
| Market Cap | 264.88M |
| Revenue (ttm) | -110,331 |
| Net Income (ttm) | -34.34M |
| Shares Out | 48.16M |
| EPS (ttm) | -1.30 |
| PE Ratio | n/a |
| Forward PE | 6.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,740 |
| Open | 5.97 |
| Previous Close | 5.40 |
| Day's Range | 5.50 - 6.22 |
| 52-Week Range | 4.73 - 8.73 |
| Beta | 0.12 |
| Analysts | Buy |
| Price Target | 8.94 (+62.5%) |
| Earnings Date | n/a |
About OPT
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related ... [Read more...]
Financial Performance
In 2021, Opthea's revenue was 68,613, an increase of 16.17% compared to the previous year's 59,061. Losses were -45.34 million, 307.7% more than in 2020.
Financial numbers in AUD Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for OPT stock is "Buy." The 12-month stock price forecast is 8.94, which is an increase of 62.55% from the latest price.
News
Opthea To Present at Upcoming Investor Conferences
MELBOURNE, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal d...
Opthea Presentation at The Retina World Congress 2022
MELBOURNE, Australia, May 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressi...
Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO...
MELBOURNE, Australia., May 05, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progres...
Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting
MELBOURNE, Australia, April 29, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progres...
Opthea strengthens its Board of Directors
Elects Mr. Quinton Oswald and Dr. Susan Orr, deeply experienced Ophthalmology Executives, at a General Meeting of Shareholders Elects Mr. Quinton Oswald and Dr. Susan Orr, deeply experienced Ophthalmolo...
Opthea To Present at Oppenheimer's 32nd Annual Healthcare Conference
MELBOURNE, Australia, March 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal...
Opthea Expands Leadership Team with the Appointment of Joel Naor, M.D., M.Sc., MBA as Chief Medical Officer
MELBOURNE, Australia, March 02, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progres...
Opthea Shares OPT-302 data In Patients With Subtype Of Age-Related Macular Degeneration
Opthea Limited's (NASDAQ: OPT) OPT-302 data were presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference. The data presented was a prespecified subgroup ana...
Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022
Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Opthea's Phase 2b clinical trial of OPT-302 in combination with ranibizumab...
Opthea To Present at SVB Leerink Global Healthcare Conference
MELBOURNE, Australia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...
Opthea Announces Presentation at the Angiogenesis, Exudation, and Degeneration 2022 Conference
MELBOURNE, Australia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...
Opthea Receives A$6.6 m R&D Tax Incentive
MELBOURNE, Australia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...
Opthea To Present at H.C. Wainwright BIOCONNECT Virtual Conference
MELBOURNE, Australia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal ...
Opthea Appoints Chief Commercial Officer to Lead Commercialization of OPT-302 for Wet AMD
MELBOURNE, Australia, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...
Opthea Granted Chinese Patent Covering OPT-302
MELBOURNE, Australia, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...
Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD
MELBOURNE, Australia, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...
Opthea To Present at September Investor Conferences
MELBOURNE, Australia, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal...
Opthea Reports Fiscal Year 2021 Financial Results and Corporate Highlights
Treated First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet Age-Related Macular Degeneration (AMD)
Opthea Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada
MELBOURNE, Australia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...
Why Opthea Stock Skyrocketed Today
The big gain appears to be a sympathy move related to positive news for another drugmaker.
Opthea Appoints Julia A. Haller, MD, and Judith Robertson to Board of Directors
MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...
Opthea Company Secretary Resignation
MELBOURNE, Australia, April 06, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT) advises that Mr Michael Tonroe has resigned as Company Secretary and Chief Financial Officer (CFO) of the Co...
Opthea Receives FDA Waiver for Pediatric Study Plan for OPT-302 in Wet AMD
MELBOURNE, Australia, March 31, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progres...
Opthea Treats First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet AMD
MELBOURNE, Australia, March 15, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progre...
Opthea to Present at the Oppenheimer 31st Annual Healthcare Conference
MELBOURNE, Australia, March 10, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progre...